These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 26612451)

  • 21. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
    Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug.
    Lee Y; Kim HY; Lee SH; Lim KY; Lee GK; Yun T; Han JY; Kim HT; Lee JS
    Clin Lung Cancer; 2014 Mar; 15(2):145-51. PubMed ID: 24342626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
    Chen H; Yao W; Chu Q; Han R; Wang Y; Sun J; Wang D; Wang Y; Cao M; He Y
    Cancer Lett; 2015 Dec; 369(1):97-102. PubMed ID: 26341687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Gou LY; Li AN; Yang JJ; Zhang XC; Su J; Yan HH; Xie Z; Lou NN; Liu SY; Dong ZY; Gao HF; Zhou Q; Zhong WZ; Xu CR; Wu YL
    Oncotarget; 2016 Aug; 7(32):51311-51319. PubMed ID: 27259997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
    Koyama N; Uchida Y
    Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
    Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L
    Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
    Jin Y; Shao Y; Shi X; Lou G; Zhang Y; Wu X; Tong X; Yu X
    Oncotarget; 2016 Sep; 7(38):61755-61763. PubMed ID: 27528220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
    Zhou S; Hu X; Wang Y; Li J; Zhou L; Hao X; Liu Y; Shi Y
    Asia Pac J Clin Oncol; 2019 Jun; 15(3):166-171. PubMed ID: 30311393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
    Pluquet E; Cadranel J; Legendre A; Faller MB; Souquet PJ; Zalcman G; Perol M; Fraboulet G; Oliveiro G; De Fraipont F; Quoix E; Lantuejoul S; Milleron B; Moro-Sibilot D
    J Thorac Oncol; 2010 Apr; 5(4):491-6. PubMed ID: 20195171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M
    Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
    Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
    Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.
    Cheng N; Cai W; Ren S; Li X; Wang Q; Pan H; Zhao M; Li J; Zhang Y; Zhao C; Chen X; Fei K; Zhou C; Hirsch FR
    Oncotarget; 2015 Sep; 6(27):23582-93. PubMed ID: 26160838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.
    Kuo CH; Lin SM; Lee KY; Chung FT; Hsieh MH; Fang YF; Yu CT; Kuo HP
    Clin Lung Cancer; 2010 Jan; 11(1):51-6. PubMed ID: 20085868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
    Lei L; Wang WX; Zhu YC; Li JL; Fang Y; Wang H; Zhuang W; Zhang YB; Wang LP; Fang MY; Xu CW; Wang XJ; Lv TF; Song Y
    Cancer Med; 2020 Jan; 9(1):12-18. PubMed ID: 31692291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
    Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients.
    Pan SH; Su KY; Spiessens B; Kusuma N; Delahaye NF; Gruselle O; Myo A; de Creus A; Louahed J; Chang GC; Yu SL; Yang PC
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e212-e223. PubMed ID: 27519286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
    Song Z; Yu X; Cai J; Shao L; Lin B; He C; Zhang B; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):138-43. PubMed ID: 23514942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.